Medacta Corporate
300,000 AMIS PROCEDURES WORLDWIDE!

300,000 AMIS PROCEDURES WORLDWIDE!

We are proud to announce that in May 2018 we reached the significant milestone of 300,000 AMIS PROCEDURES WORLDWIDE!

 

AMIS (Anterior Minimally Invasive Surgery) is a hip replacement technique that follows both an intermuscular and internervous path to greatly decrease damage to periarticular structures while preserving tissue and which is supported by the industry’s most detailed surgeon training protocol. 
 
The promotion of patient well-being through AMIS is a cornerstone of Medacta’s mission, as it exemplifies our belief that only with a strong focus on medical education can surgical innovation truly move the industry forward,” said Francesco Siccardi, Executive Vice President of Medacta International. “The patient-centric technique is also ideal for the outpatient or same-day surgery settings, providing more options for both surgeons and patients in today’s changing healthcare landscape.
 
Today, the AMIS technique evolved into the concept of the AMIS Experience, as it is much more than just a surgical technique, it is a complete set of services which provides for healthcare efficiency supportive of economic and commercial advantages for the hospital & surgeon.
 
Within the AMIS Experience it is possible to take advantage of:
 
SURGICAL TECHNIQUE: AMIS is an evolution of the anterior approach: simpler, more reproducible and less invasive.
 
MEDICAL EDUCATION: The M.O.R.E. AMIS Education Program is a tested and proven method of top level continuous education which effectively helps to smooth the learning curve.
 
DEDICATED IMPLANTS: Specifically developed to make their implantation easier through the anterior approach, supported by clinical evidence and customer success
  • AMIStem-H and QUADRA-H have been awarded the 7A rating by the ODEP Panel
  • AMIStem-H: 98.9% survival rate (Kaplan-Meier method) including any reason for revision as endpoint, at minimum 5 years follow-up[1] 
  • QUADRA-H: ONLY 1 revision for aseptic loosening out of 283 cases (survival rate of 99.65% with aseptic loosening as endpoint), at a minimum follow-up of 10 years[2]
  • Versafitcup CC Trio: 98.6% survival rate including any reason for revision as endpoint, at minimum 10 years follow-up[2]
ADVANCED INSTRUMENTATION: Developed specifically to make the AMIS technique an easier and more reproducible procedure.
 
TOOLS AND SERVICES: Extras provided by Medacta to further support a surgeon’s practice.
 
 
MORE THAN 100 PUBLICATIONS AS CLINICAL EVIDENCE[3]

 
[1] Kalberer F, Krupp F, Molnar V, Schmied-Steinbach A, Schläppi M. AMIStem-H: Radiological results at 5 years. M.O.R.E. Journal Supplement, July 2016
[2] Rahm S, Tondelli T, Steinmetz S, Schenk P, Dora C, Zingg P. Versafit Cup and Quadra Stem in THA Through the Direct Anterior Approach: Analysis of a Consecutive Series of 283 Hips with a Minimum Follow-up of 10 years. Podium presentation at the 78th Annual Congress of the Swiss Orthopaedics Jahreskongress, Montreux, Switzerland, June 6-8, 2018
[3] AMIS Publication Review – M.O.R.E. Journal Supplement, April 2016. 99.98.publ rev.01